MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Marc Hoffmann, Shuo Ma, Herbert Eradat, Constantine Tam, Masa Lasica, Paul Hampel, Emma Verner, Lori Leslie, Christopher D'Angelo, Jacob Soumerai, Mazyar Shadman, Chan Cheah, Monica Tani, Yiqian Fang, Binghao Wu, Gabriel Man, Sheel Patel, Remus Vezan, Stephen Opat
Institutions: The University of Kansas Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of California, Los Angeles, The Alfred Hospital, Monash University, St Vincent's Hospital Melbourne, Mayo Clinic, The University of Sydney, Concord Repatriation General Hospital, Hackensack University Medical Center, Nebraska Medical Center, University of Nebraska Medical Center, Harvard University, Massachusetts General Hospital, University of Washington, Fred Hutch Cancer Center, The University of Western Australia, Sir Charles Gairdner Hospital, Linear Clinical Research, Ospedale "Santa Maria delle Croci" di Ravenna, Monash Health
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417011664